• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

AbbVie axes midstage Alzheimer's program amid 'evolving landscape'

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 25, 2024 at 11:32: AM
via AbbVie is discontinuing solo development of a midstage Alzheimer’s disease candidate, a monoclonal antibody that failed to differentiate itself against already approved treatments.

article source
 

<



Similar threads

cafead
AstraZeneca steps out from Daiichi&#039;s shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
UnitedHealth to remove AbbVie&#039;s Humira from some US drug reimbursement lists next year
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie sues rival BeiGene over alleged theft of cancer therapy secrets
Replies
0
Views
22
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie&#039;s Ubrelvy wards off migraines when used in reaction to early warning signs: study
Replies
0
Views
17
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Cigna to remove AbbVie&#039;s Humira from some drug reimbursement lists next year
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote